Radio-Immunology of Ablative Radiation Therapy

This chapter explores the synergistic potential of ablative radiation therapy (ART), including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), and stereotactic ablative radiotherapy (SABR), in the context of tumor immunity and cancer treatment. The advent of advanced radiation technologies, such as image-guided radiation therapy (IGRT) alongside SRS, SBRT, and SABR, has markedly enhanced the precision of tumor targeting. This precision allows for the delivery of high ablative doses of radiation to tumors while minimizing damage to surrounding healthy tissue, achieving local control rates comparable to those of surgical interventions. The review highlights the dual role of ablative radiation in directly targeting tumors and enhancing their immunogenicity. This is achieved by releasing tumor-derived antigens and danger-associated molecular pattern (DAMP) ligands, which facilitate the induction of antitumoral immunity and tumor cell immunomodulation. The immunological impact of various radiation schedules, from conventional fractionation to short courses of stereotactic radiation, is discussed, emphasizing the multifactorial nature of these effects and their sometimes counterproductive consequences on tumor clearance by immune effector cells. The tumor microenvironment, often characterized by diminished immune responses and increased immune suppression, is identified as a critical factor influencing the efficacy of radiation therapy. The chapter underscores the importance of integrating ART with immunotherapy, outlining a future research and clinical practice roadmap. This integration considers factors such as radiation dose and fractionation, types of immunotherapeutic agents, and the baseline immunophenotype of the tumor, aiming to tailor treatment modalities to patients’ disease phenotypes for enhanced local and systemic control. Clinical evidence supporting the efficacy of ART, with over 90% local control of irradiated tumors, is reviewed, along with immune mechanisms of radiation-induced tumor cell death, including mitotic catastrophe, apoptosis, and necrosis. The challenges of immune suppression and strategies to overcome these obstacles are also discussed. By focusing on the synergistic potential of ART and immunotherapy, the review proposes a comprehensive approach to cancer treatment that targets tumors directly and mobilizes the body’s immune response, offering a promising pathway to improved patient outcomes and the advancement of cancer therapy.